BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Safety Signal Leads Centessa to Discontinue Development of Lead Asset

  Centessa announced Thursday it is discontinuing the development of its lead asset, lixivaptan, for autosomal dominant polycystic kidney disease (ADPKD).

  June 2, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: Gene Regulation and Longevity, Comparing COVID-19 Vaccines

  Top research stories, including gene regulation and longevity, a head-to-head comparison of COVID-19 vaccines, a newly discovered type of brain cell and more.

  June 2, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Outbreak Updates: Monkeypox Highlights Animal-to-Human Interface, Dogs Sniff Out COVID-19

  Monkeypox is not COVID-19, but both are viral diseases that are front-and-center in the world of public health and epidemiology. Here’s a look at the latest news on both outbreaks.

  June 2, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances

  With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.

  June 2, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Numinus CEO: Psychedelic-assisted Psychotherapy Still Driven by Perceptions

  BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.

  June 2, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Drug Development

  Atreca Slashes One-Fourth Of Workforce in Reorganization Strategy

  Atreca is reducing its staff count by over 25%, covering current employees and open roles, and revising its operating plan to reflect these cost-cutting measures.

  June 2, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  BMS-Backed Transition Bio Scores $50M to Mine Biomolecular Condensates for Therapeutic Use

  Transition Bio has a four-component platform called Condensomics which provides a technological method to understand the properties of condensates.

  June 2, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Upstream Bio Dives into Severe Asthma Space with $200M in Series A Financing

  Upstream Bio is focusing its efforts on an experimental treatment for severe asthma licensed from Astellas Pharma.

  June 2, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Deals

  Regeneron to Buy Sanofi’s Stake in Libtayo for $900M Upfront

  Regeneron Pharmaceuticals announced intentions to acquire Sanofi’s stake in a drug they developed together, Libtayo (cemiplimab).

  June 2, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Flagship’s Tessera Wins Services of Ex-AbbVie Exec Severino

  Tessera Therapeutics announced Thursday that ex-AbbVie executive Michael Severino, M.D. will take the helm of the young biotech.

  June 2, 2022

   · 

  2 min read

   · 

  Paul Besabella